Osteogenics Biomedical, Inc. Sustainability Profile
Osteogenics Biomedical, Inc., a leading name in the regenerative medicine industry, is headquartered in the United States. Founded in 1996, the company has established itself as a pioneer in the development of innovative bone grafting solutions and dental regenerative products. With a focus on enhancing patient outcomes, Osteogenics offers a range of unique products, including advanced bone graft materials and barrier membranes, designed to support dental and orthopaedic procedures. The company has achieved significant milestones, including numerous patents and recognitions for its contributions to the field. Osteogenics Biomedical is well-regarded for its commitment to quality and innovation, positioning itself as a trusted partner for dental professionals and surgeons across major operational regions in North America and beyond.
DitchCarbon Score
How does Osteogenics Biomedical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Osteogenics Biomedical, Inc.'s score of 36 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Osteogenics Biomedical, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Envista Holdings Corporation, which may influence its climate commitments and reporting practices. While Osteogenics Biomedical has not established its own reduction targets or climate pledges, it is important to note that it inherits data and initiatives from its parent company, Envista Holdings Corporation. This relationship may provide a framework for future climate action and emissions reporting. As of now, Osteogenics Biomedical has not publicly committed to any specific science-based targets or reduction initiatives. The absence of detailed emissions data suggests that the company may still be in the early stages of developing its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 7,060,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 20,890,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Osteogenics Biomedical, Inc.'s Industry?
How Carbon Intensive is Osteogenics Biomedical, Inc.'s Location?
Osteogenics Biomedical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Osteogenics Biomedical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
